Clinical Trial Update: Macitentan in Pulmonary Hypertension of Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of macitentan for pulmonary hypertension associated with sickle cell disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Sickle Cell Disease

Drugs mentioned

• Macitentan (macitentan)

Snippet

Sponsor: Boston University | Conditions: Pulmonary Hypertension, Sickle Cell Disease | Phase 2 | Status: TERMINATED | Results posted: 2020-12-08